新型口服抗凝药达比加群酯治疗老年非瓣膜性房颤患者的疗效和安全性研究

Research on curative effects and safety of a novel oral anticoagulant dabigatran etexilate in treatment of elderly patients with non-valvular atrial fibrillation

目的分析探讨新型口服抗凝药达比加群酯治疗老年非瓣膜性房颤的临床疗效和安全性。方法随机从我院2016年5月~2017年10月收治的老年非瓣膜性房颤患者中抽取80例进行分析,依据其治疗方式分组,其中40例接受华法林治疗(对照组),另40例接受达比加群酯治疗(研究组),观察比较治疗状况。结果研究组出血率为2.50%、卒中率为2.50%、血栓栓塞率为2.50%低于对照组的20.00%、17.50%、17.50%,差异有统计学意义(P<0.05)。研究组不良反应总发生率为5.00%低于对照组27.50%,差异有统计学意义(P<0.05)。治疗前凝血指标组间比较,差异无统计学意义(P>0.05),治疗后,研究组PLT、FIB、PT、抗凝血酶Ⅲ高于对照组,INR低于对照组,差异有统计学意义(P<0.05),APTT比较,差异无统计学意义(P>0.05)。结论分析后得知,新型口服抗凝药达比加群酯治疗老年非瓣膜性房颤,其疗效与华法林一致,但安全性更高,值得推广。

Objective To analyze and explore clinical curative effects and safety of a novel oral anticoagulant dabigatran etexilate in treatment of elderly patients with non-valvular atrial fibrillation. Methods 80 elderly patients with non-valvular atrial fibrillation who were admitted and treated in our hospital from May 2016 to October 2017 were randomly selected and analyzed.According to treatment methods,they were divided into two groups.40 patients in the control group were treated with warfarin while 40 patients in the study group were treated with dabigatran etexilate. The treatment status was observed and compared. Results The bleeding rate,stroke rate and thromboembolism rate of the study group were respectively 2.50%,2.50% and 2.50%,lower than 20.00%,17.50% and 17.50% of the control group.The difference in data between the groups was statistically significant (P < 0.05).The overall incidence of adverse reactions in the study group was 5.00%,lower than that in the control group (27.50%).The difference in data between the groups was statistically significant (P < 0.05).Coagulation indexes were compared,and there was no statistically significant difference between the groups before treatment (P > 0.05).After treatment,PLT,FIB, PT and antithrombin Ⅲ in the study group were higher than those in the control group,and INR was lower than those in the control group.The difference in data between the groups was statistically significant (P < 0.05).APTT comparison showed no statistical significance between groups (P > 0.05). Conclusion According to the analysis,the novel oral anticoagulant dabigatran etexilate in treatment of elderly patients with non-valvular atrial fibrillation has the same curative effects as warfarin,but the safety is higher.It is worthy of promotion.